<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043587</url>
  </required_header>
  <id_info>
    <org_study_id>130934</org_study_id>
    <nct_id>NCT02043587</nct_id>
  </id_info>
  <brief_title>Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma</brief_title>
  <official_title>A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leadiant Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this protocol is to improve survival for adults with acute lymphoblastic
      leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system
      (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine
      (Depocyt®) CNS prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This treatment regimen builds on the &quot;Linker&quot; regimen/UCSF Protocol 8707 ALL regimen backbone
      with the goal of improved efficacy and acceptable toxicity by substituting pegylated
      asparaginase for native L-asparaginase, the addition of rituximab for pre-B-cell ALL, and the
      addition of dasatinib for Philadelphia chromosome/BCR-ABL positive ALL, and the addition of
      cyclophosphamide for younger adults. In addition, the study regimen aims to reduce CNS
      relapse through the use of intrathecal liposomal cytarabine in place of intrathecal
      methotrexate for CNS relapse prophylaxis and

      The regimen uses 3 modules of therapy with non-cross-resistant chemotherapy agents. Rituximab
      is added for a total of 8 doses for patients with pre-B-cell ALL. Dasatinib is added for
      patients with Ph+ ALL.

      Course 1A (Induction): Daunorubicin, vincristine, PEG-asparaginase, and prednisone for all
      patients with the addition of cyclophosphamide for patients 18-39 years of age. Treatment is
      intensified for patients with disease present on a day 14 bone marrow biopsies during
      Induction Course 1A. In addition to standard analyses, minimal residual disease will be
      assessed on day 14 and remission bone marrow aspirates and correlated with outcomes.

      Course 1B: High-dose methotrexate, oral 6-mercaptopurine, and PEG-asparaginase.

      Course 1C: High-dose cytarabine and etoposide.

      The 3 courses then repeat (2A (Intensification), 2B, 2C) followed by a final &quot;B&quot; cycle (3B)
      of high-dose methotrexate, 6-mercaptopurine, and PEG-asparaginase.

      After completion of Course 3B, patients proceed to maintenance chemotherapy with monthly
      methotrexate, vincristine, 6-mercaptopurine, and prednisone cycles for 24 months with a
      single dose PEG-asparaginase given in month 1 of Maintenance.

      CNS prophylaxis: Intrathecal liposomal cytarabine replaces intrathecal methotrexate CNS
      prophylaxis and is given every 2 weeks during the &quot;A&quot; Induction and Intensification courses
      then every 3 months during Maintenance for a total of 8 doses. Given the presence of CNS
      penetrating chemotherapy in the &quot;B&quot; and &quot;C&quot; cycles, intrathecal liposomal cytarabine is not
      given due to risk of excessive CNS toxicity.

      There is a randomization to hydrocortisone or placebo premedication prior to
      PEG-asparaginase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>3-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liposomal cytarabine toxicity</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS relapse rate</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of hydrocortisone premedication for reduced PEG-asparaginase allergic reactions</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEG-asparaginase toxicities</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete and overall response rates</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Minimal residual disease and outcomes</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Asparaginase antibodies and asparaginase activity</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Adult Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age &gt;50); PEG-asp 2000 IU/m2 IV d16, age &gt;50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age &lt; 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15
1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX &lt;0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age &gt;50 1000 IU/m2, cap 3750 IU/m2
1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4
1A-C repeat x1(2A-C) then 3rd Course B (3B)
Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age &gt;50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age &gt;50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)
Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1
Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)
1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, &amp; Maint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNR</intervention_name>
    <description>Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Daunorubicin</other_name>
    <other_name>Daunorubicin Hydrochloride</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>Daunomycin</other_name>
    <other_name>Rubidomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VCR</intervention_name>
    <description>1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages &gt;50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Vincristine</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>PFS</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Leurocritine</other_name>
    <other_name>LCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-asp</intervention_name>
    <description>2,000 IU/m2 IV for ages &lt;/= 50, age &gt; 50, 1000 IU/m2 IV Day 16, Courses 1A &amp; 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>PEG-L-asparaginase</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>PEG-asparaginase</other_name>
    <other_name>pegasparagase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX</intervention_name>
    <description>750 mg/m2 IV, days 1 &amp;15 for subjects &lt;40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 &amp; 16 for subjects &lt; 40 years of age if day 14 bone marrow M2 or M3; Courses 1A &amp; 2A</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
    <other_name>CPM</other_name>
    <other_name>CYT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>60 mg/m2 orally once daily on days 1-28 during Courses 1A &amp; 2A; Maintenance: Monthly, days 1-5</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Deltasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal AraC</intervention_name>
    <description>25 mg intrathecal (IT), on days 1 &amp; 15 during Courses 1A &amp; 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Liposomal cytarabine</other_name>
    <other_name>DepoCyt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B &amp; 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Methotrexate</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Trexall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCV</intervention_name>
    <description>50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B &amp; 2B</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AraC</intervention_name>
    <description>2,000 mg/m2 IV, days 1-4 during Courses 1C &amp; 2C</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Cytarabine</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C &amp; 2C</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>VePesid</other_name>
    <other_name>Toposar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>140 mg orally daily if BCR/ABL positive and/or Ph+</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 IV once daily on days 1 &amp; 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C &amp; 2A</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1</description>
    <arm_group_label>Chemotherapy for ALL</arm_group_label>
    <other_name>Hydrocortisone sodium succinate</other_name>
    <other_name>Solu-Cortef</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and the willingness to sign a written informed consent.

          -  Diagnosis of acute lymphoblastic leukemia or lymphoblastic lymphoma as defined by the
             World Health Organization [94]

          -  Untreated disease EXCEPT for corticosteroids, hydroxyurea, leukapheresis, and/or
             tyrosine kinase inhibitors for up to 2 weeks prior to initiation of study therapy.

          -  Age 18 through 60 years

          -  ECOG performance status 0,1, or 2 (see Appendix A)

          -  Adequate organ function defined as:

          -  Total bilirubin &lt; 2 mg/dL (unless due to ALL)

          -  AST(SGOT)/ALT(SGPT) &lt; 3 times institutional upper limit of normal (unless due to ALL)

          -  Serum creatinine &lt; 2 mg/dL (unless elevated creatinine felt by investigator to be
             acute and reversible) OR creatinine clearance &gt;60 mL/min/1.73 m2 for patients with
             creatinine levels above institutional normal

          -  Left ventricular ejection fraction ≥50%

          -  Women of child-bearing potential and men with partners of child- bearing potential
             must agree to use adequate contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry, for the duration of study participation, and for 90
             days following completion of therapy. Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately.

          -  A woman of child-bearing potential is any female (regardless of sexual orientation,
             having undergone a tubal ligation, or remaining celibate by choice) who meets the
             following criteria:

               -  Has not undergone a hysterectomy or bilateral oophorectomy; or

               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
                  has had menses at any time in the preceding 12 consecutive months)

        Exclusion Criteria:

          -  Current or anticipated use of other investigational agents during the study

          -  Known central nervous system mass lesion

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to liposomal cytarabine or other agents used in study inclusive of known
             allergy to polyethylene glycol.

          -  History of unprovoked venous thrombosis/thromboembolism

          -  Recurrent or chronic pancreatitis

          -  Uncontrolled diabetes mellitus

          -  Uncontrolled intercurrent illness that would limit compliance with study requirements
             including, but not limited to, ongoing or active infection, symptomatic congestive
             heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements.

          -  Pregnant or nursing.

          -  Any condition, in the opinion of the investigator, that compromises compliance with
             study requirements

          -  Known HIV positivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J Wieduwilt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego, Division of Blood and Marrow Transplantation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew J Wieduwilt, MD, PhD</last_name>
    <phone>858-822-6848</phone>
    <email>mwieduwilt@ucsd.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSD, Division of Blood and Marrow Transplantation, Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew J Wieduwilt, M.D., Ph.D</last_name>
      <phone>858-822-6848</phone>
      <email>mwieduwilt@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew J Wieduwilt, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Jonas, MD, PhD</last_name>
      <phone>916-734-5959</phone>
      <email>bajonas@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lloyd E Damon, M.D.</last_name>
      <phone>415-353-2737</phone>
      <email>damonl@medicine.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Lloyd E Damon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002 May 15;20(10):2464-71.</citation>
    <PMID>12011123</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Matthew Wieduwilt, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Lymphoblastic leukemia</keyword>
  <keyword>Lymphoblastic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

